Sounds like MRK has big expectations for this candidate. I thought they will do a smaller phase II for safety and biomarkers data only. This big trial should also be powered for efficacy. It isn't in clinicaltials.gov yet, guess it will start later this year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.